Winder, Gary 1943-2025 St. Joseph, Mo.
He was preceded in death by his parents; a sister, Nancy Fredrickson; and a nephew, Steven E. Fredrickson.
Survivors include brother, James (Connie) Winder, of Maine; nieces, Angie Giegerich, Tracy Kerner, and Stacey Skinsacos; nephews, Scott and Stephen Winder.
Graveside funeral services and interment will be conducted on Friday, July 10, 2025, at 10:30 a.m. at the Mount Auburn Cemetery. Memorials are requested to Juvenile Diabetes and an organization of donors choice.
Online condolence and obituary at www.ruppfuneral.com. As published in the St. Joseph News-Press.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
26 minutes ago
- Washington Post
Asking Eric: Wife left a gift to niece in her will, but I hesitate to honor it
Dear Eric: When my wife and I updated our wills, she designated a diamond tennis bracelet and diamond stud earrings to her niece (she had no biological children of her own). Later that month my wife was diagnosed with pancreatic cancer to which she would succumb 19 months later. My daughter (my wife's stepdaughter) is a radiation oncologist and became our daily advocate as we navigated the byzantine world of cancer treatment.
Forbes
an hour ago
- Forbes
Sell HIMS Stock Ahead of Its Earnings?
Hims & Hers Health (NYSE:HIMS) is set to announce its earnings on Monday, August 4, 2025. Historically, HIMS stock has reacted unfavorably to earnings announcements. Since 2021, the stock has recorded a negative one-day return in 53% of instances after results. The median one-day decline has amounted to -5.8%, with a maximum one-day decrease of -22.3%. For traders focused on events, grasping these historical trends can be beneficial. While the actual results compared to consensus and expectations will be vital, there are two main strategies to contemplate: Analysts expect HIMS to report earnings of $0.23 per share on revenues of $552 million. This would mark substantial growth compared to the same quarter last year, which recorded earnings of $0.16 per share on revenues of $315 million. A possible positive factor for Hims & Hers' sales growth momentum is the reported underperformance of Novo Nordisk's weight loss medication in the U.S. due to the presence of compounded versions. Regarding fundamentals, HIMS has a market capitalization of $15 billion. Over the past twelve months, the company generated $1.8 billion in revenue and was operationally profitable, reporting $110 million in operating profits and a net income of $164 million. However, if you're looking for upside with less volatility than individual stocks, the Trefis High Quality portfolio offers an alternative — it has outperformed the S&P 500 and achieved returns exceeding 91% since its inception. Additionally, see – Is There More Upside For MSFT Stock? Review earnings reaction history of all stocks HIMS Stock Historical Likelihood of Positive Post-Earnings Return Here are some insights on one-day (1D) post-earnings returns: Additional information regarding the observed 5-Day (5D) and 21-Day (21D) returns post earnings is summarized along with the statistics in the table below. HIMS Stock Correlation Between 1D, 5D, and 21D Historical Returns A comparatively lower-risk strategy (though not effective if the correlation is weak) is to understand the relationship between short-term and medium-term returns post earnings, identify a pair that has the highest correlation, and perform the corresponding trade. For instance, if 1D and 5D exhibit the highest correlation, a trader can take a "long" position for the next 5 days if the 1D post-earnings return is positive. Here is some correlation information based on a 5-year and 3-year (more recent) timeframe. Note that the correlation 1D_5D denotes the relationship between 1D post-earnings returns and subsequent 5D returns. Discover more about the Trefis RV strategy that has outperformed its all-cap stocks benchmark (a blend of the S&P 500, S&P mid-cap, and Russell 2000), delivering strong results for investors. Additionally, if you seek upside with a smoother experience than an individual stock like Hims & Hers Health, consider the High Quality portfolio, which has surpassed the S&P and yielded >91% returns since its inception.
Yahoo
an hour ago
- Yahoo
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, July 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Wednesday, August 13, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's second quarter 2025 financial results. The webcast will be available at the investor relations section of the Company's website at Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join. Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at About Lucid DiagnosticsLucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients. For more information, please visit and for more information about its parent company PAVmed, please visit View original content to download multimedia: SOURCE Lucid Diagnostics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
